Navigation Links
New sickle cell anemia therapy advances to Phase II clinical trials
Date:6/12/2013

reatening problems."

The sickle cell trial grew out of research by Dr. Linden, who is a leading expert on adenosine receptors, which are known to act as a natural brake on inflammation. While Dr. Linden had previously explored adenosine's role in protecting tissues from damage due to low blood flow in single tissues such as in heart disease, he was struck one day with the idea that it might also protect people with sickle cell disease, who suffer tissue damage from poor blood flow to most tissues.

Dr. Linden began testing his theory in mouse models about four years ago and found that adenosine-like compounds significantly reduced the damaging effects of the disease. He was aware of an existing FDA approved adenosine-like drug, Lexiscan that had already been approved for another use. "This was good news since it meant that Lexiscan was known to be safe in humans and could probably gain rapid approval if proven effective in clinical trials as a treatment for sickle cell disease," he said.

Dr. Linden joined forces with Dr. Nathan, who participated in the development of the only existing FDA-approved drug for sickle cell treatment, hydroxyurea, and another clinical collaborator, Dr. Field, to seek NIH funding for the Lexiscan trial. They launched the trial's first phase in 2010 using patient volunteers from Brigham and Women's Hospital in Boston and Washington University in St. Louis.

In the trial, Dr. Nathan, Dr. Field and other clinicians collected blood from patients and sent it to Dr. Linden in La Jolla for analysis of white blood cell inflammation. Gene Lin, Ph.D., a scientist in Linden's lab, has been a significant contributor to the analysis effort. The same protocol will be used in the trial's second phase.

Lexiscan is approved as a pharmacologic stress agent used for myocardial perfusion imaging (MPI), a procedure that measures coronary blood flow to help in the diagnosis of heart disease. Lexiscan is u
'/>"/>

Contact: Bonnie Ward
contact@liai.org
619-303-3160
La Jolla Institute for Allergy and Immunology
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Sickle cell trait can cause sudden cardiac death in black athletes: Why is this controversial?
2. Potential gene therapy approach to sickle cell disease highlighted at ASH
3. Nature study reveals loss of essential blood cell gene leads to anemia
4. Why a hereditary anemia is caused by genetic mutation in mechanically sensitive ion channel
5. Cleveland Clinic research shows anemia drug does not improve health of anemic heart failure patients
6. Discovery may help prevent chemotherapy-induced anemia
7. Scientists identify potential drug target for treatment-resistant anemias
8. Stanford scientists develop gene therapy approach to grow blood vessels in ischemic limbs
9. Ottawa researchers to lead world-first clinical trial of stem cell therapy for septic shock
10. New insight into mechanisms behind autoimmune diseases suggests a potential therapy
11. The Japanese traditional therapy, honokiol, blocks key protein in inflammatory brain damage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/wxdglm/global_wearable ... "Global Wearable Technologies Market and Applications, Opportunities, Industry ... Forecast 2014-2020" report to their offering. ... that can be worn on the user,s body ...
(Date:1/22/2015)... , Jan. 22, 2015 Infinisource has launched its ... the G2 model. The G2 sets a higher standard for ... human capital management solution. With plug-and-play installation, touch screen interface ... clock provides a robust time collection solution for the small ...
(Date:12/22/2014)...  NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) ("NXT-ID" ... growing mobile commerce market, announces it has retained famous pickpocket, ... 2015 International CES debut of the Wocket™ biometric smart wallet.  ... the NXT-ID booth January 6th and 7 th , 2015, ...
Breaking Biology News(10 mins):Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2Infinisource's NXG series sets new time clock standard 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4
... European universities, research institutes, and companies, led by ... a 6 year programme supported by the Innovative ... Gram-negative pathogens. The project, called ENABLE (European Gram-Negative ... the consortium. The antibiotic crisis ...
... Scientists from the Monell Center have used analytical ... compounds in human earwax. Further, they found that the ... Asian origin and Caucasians. The findings suggest that human ... overlooked source of personal information. "Our previous ...
... Arvizu, director of the Energy Department,s National Renewable ... in the National Academy of Engineering. Election ... the highest professional distinctions accorded to an engineer. ... contribution to engineering research, practice or education and ...
Cached Biology News:€85 million for new way to carry out antibiotic drug discovery 2Earwax: A new frontier of human odor information 2NREL director Arvizu elected to National Academy of Engineering 2
(Date:2/27/2015)... GERMANTOWN, Md. and SUMMERLAND, British ... Corporation (NYSE: XON ), a leader ... an agreement to acquire  Okanagan Specialty Fruits (OSF), ... apple , the world,s first non-browning apple. Through ... trees yielding fruit that is more appetizing and convenient ...
(Date:2/27/2015)... DUBLIN , Feb. 27, 2015 Research and Markets ... the "Global Market Report of Trypsin" report to ... Trypsin (CAS 9002-07-7) aims at providing comprehensive data on Trypsin ... Asia , North America , ... trends, pays close attention to Trypsin This report ...
(Date:2/27/2015)... , Feb. 27, 2015 Bionomics Limited (ASX:BNO, ... DisrupTOR-1 trial of BNC105 in patients with metastatic renal ... Orlando, Florida . The data will be ... City of Hope Comprehensive Cancer Center in ... The new data identifies Ferritin and IL-8 as ...
(Date:2/27/2015)... Cytokinetics, Incorporated (Nasdaq: CYTK) announced today ... patients and health care advocates in the United States ... Rare Disease Day is dedicated to elevating public ... special challenges faced by patients with rare diseases and ... to stand alongside patients and caregivers representing the rare ...
Breaking Biology Technology:Intrexon to Acquire Okanagan Specialty Fruits 2Intrexon to Acquire Okanagan Specialty Fruits 3Intrexon to Acquire Okanagan Specialty Fruits 4Global Market Report of Trypsin 2014-2018 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 6
... Building for the Future, CAMBRIDGE, Mass., July 23 ... sales and profit growth in the second,quarter, along with ... increased 25 percent to approximately $1.171 billion from,$933.4 million ... by,growth across all areas of the business., GAAP ...
... . , The polymer researchers at the ... scientists to attend the kick-off meeting of the new ... New kinds of plastic-based nanocomposites could be used to ... of materials and add electrical or magnetic properties, for ...
... PharmaSmart International Inc, a Rochester, NY company today announced it is ... HBC industry leader, to head up global sales and marketing. ... ... a Rochester, NY company today announced it is bringing aboard Ashton ...
Cached Biology Technology:Genzyme Reports Strong Second-Quarter Growth 2Genzyme Reports Strong Second-Quarter Growth 3Genzyme Reports Strong Second-Quarter Growth 4Genzyme Reports Strong Second-Quarter Growth 5Genzyme Reports Strong Second-Quarter Growth 6Genzyme Reports Strong Second-Quarter Growth 7Genzyme Reports Strong Second-Quarter Growth 8Genzyme Reports Strong Second-Quarter Growth 9Genzyme Reports Strong Second-Quarter Growth 10Genzyme Reports Strong Second-Quarter Growth 11Genzyme Reports Strong Second-Quarter Growth 12Genzyme Reports Strong Second-Quarter Growth 13Genzyme Reports Strong Second-Quarter Growth 14Genzyme Reports Strong Second-Quarter Growth 15Genzyme Reports Strong Second-Quarter Growth 16Genzyme Reports Strong Second-Quarter Growth 17Using nanotechnology to create high-performance materials 2Pharmasmart International Taps Top Executive Ashton Maaraba to Head Global Sales and Marketing 2
... product contains 5 ml of DETACHaBEAD Mouse ... mouse CD4+ T cells from Dynabeads Mouse ... CD4+ T cells from Dynabeads Mouse CD4 ... are suitable for any downstream application including ...
Porcine IFN-gamma ELISpot Development Module...
...
Request Info...
Biology Products: